Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jun 24, 2019 at 11:32 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via Bristol-Myers Squibb has suffered another painful setback in its years-long quest to expand the reach of Opdivo. The pharma giant this morning noted that their Checkmate-459 study comparing Opdivo with Bayer’s Nexavar in frontline cases of hepatocellular carcinoma — the most common form of liver cancer — failed to hit the primary endpoint on overall survival.

    article source